Oculis Pharma raised $57 million Series C financing, co-led by BVCF Management and Hyfinity Investments

Oculis SA, a Reykjavik, Iceland and Lausanne, Switzerland-based clinical-stage biopharmaceutical company developing investigational ophthalmology drugs, announced the completion of a $57 million series C capital funding round.

The money was raised from investors co-led by China-based BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Capital Management, Pivotal bioVenture Partners, Nan Fung Life Sciences, Novartis Venture Fund, Silfurberg, as well as other existing investors.

Proceeds from this financing will accelerate Oculis’ strategy with the aim of delivering key goals in the near-term to drive shareholder value and bring transformative therapies to patients.

Oculis SA, founded in 2003 by Einar Stefansson and Thorsteinn Loftsson, is a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and lives of patients worldwide.

The company has a robust and expansive development portfolio including late-stage novel topical (eye drop) treatments, which are non-invasive and represent an unprecedented technical advance for patients with retinal edema and front-of-the-eye diseases. In addition, Oculis’ formulation discovery and innovation capabilities enable the development of a pipeline of topical drugs targeting sight-threatening eye diseases that affect both the anterior and posterior segments of the eye. 

Oculis last raised in 2019 when it held a second closing of its series B round totalling $36 million.